Biologics & Biosimilars

Biologics are medicines made from living cells through highly complex manufacturing processes and must be handled and administered under carefully monitored conditions. Biologics are used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Euro Biosimilars is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA. Under U.S. law, a biosimilar is approved based on a showing that it is “highly similar” to an FDA-approved biological product, known as a reference product. It may not have any clinically meaningful differences in terms of safety and effectiveness from the reference product.

  • Bio-analytics for biosimilars
  • Extrapolation and interchangeability

Related Conference of Biologics & Biosimilars

July 25-26, 2024

34th Annual European Pharma Congress

Frankfurt, Germany
August 06-07, 2024

27th World Congress on Nursing, Pharmacology and Healthcare

Aix-en-Provence, France
August 28-29, 2024

4th International Conference on Pharmaceutical Chemistry

Aix-en-Provence, France
September 11-12, 2024

9th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 25-26, 2024

4th World Congress on Rare Diseases & Orphan Drugs

Paris, France
October 31-01, 2024

37th World Congress on Pharmacology

Amsterdam, Netherlands
November 26-27, 2024

3rd World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2024

3rd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 28-29, 2024

39th World Congress on Pharmacology and Therapeutics

Paris, France
November 28-29, 2024

12th International Conference on Clinical Trials

Vancouver, Canada
December 05-06, 2024

17th World Drug Delivery Summit

Dubai, UAE
April 14-15, 2025

18th European Biosimilars Congress

Aix-en-Provence, France

Biologics & Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in